.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Rapid Readout: Clinical Updates in Multiple Sclerosis From CMSC 2020

EP. 1: The Multidisciplinary Theme of CMSC 2020

June 12th 2020

EP. 2: Progressive MS: The 2020 Whitaker Lecture

June 12th 2020

EP. 3: Ocrelizumab Compared to Glatiramer Acetate and Dimethyl Fumarate for MS

June 12th 2020

EP. 4: Post Hoc Analysis: Phase 3 ASCLEPIOS I and II Trials in Relapsing MS

June 12th 2020

EP. 5: Primary Results From the ENSEMBLE PLUS Study

June 12th 2020

EP. 6: Post Hoc Analysis: Phase 3 EXPAND Trial in Secondary Progressive MS

June 12th 2020

EP. 7: Open-Label Extension: Phase 3 OPERA I and II Trials in Relapsing MS

June 12th 2020

EP. 8: CMSC Data Release: Abstract DXT58 and MS Risk Reduction

June 12th 2020

EP. 9: Open-Label Extension: BTKI in Relapsing MS Over 108 Weeks

June 12th 2020

Latest News

NeuroVoices: Michael Sughrue, MD, on the Future of Brain Mapping and Utilizing Advanced Technology

The Mobile Stroke Unit Paradigm Shift for EMS: Thomas Topley

American Stroke Association Publishes Updated Guidance for Intracerebral Hemorrhage

FDA Accepts New Drug Application for Intranasal Zavegepant to Treat Acute Migraine

View More News